The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | Factors to consider when approaching R/R multiple myeloma
Ezzat El Hassadi, MD, University Hospital Waterford, Waterford, Ireland, explains the key components considered when approaching the treatment of relapsed/refractory (R/R) multiple myeloma, including patient characteristics, disease biology, and treatment toxicity. Dr El Hassadi highlights the importance of considering a patient’s prior exposure to therapies, and discusses the use of daratumumab, triplet therapy, and transplantation in this setting. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
